| Description | Eicosapentaenoic acid ethyl ester (Ethyl eicosapentaenoate) is an omega-3 fatty acid. |
| In vivo | Icosapent ethyl (IPE) 4 g/day significantly reduced large VLDL, total LDL, small LDL, and total HDL particle concentrations and VLDL particle size in patients with TG 500 mg/dL.Changes in VLDL particle concentration and size reflect the TG-lowering effects of eicosapentaenoic acid.?The reduction in LDL particle concentration with IPE is novel among ω-3 therapies and is consistent with the previously reported reduction in apolipoprotein B and lack of LDL-C increase with IPE in patients with very high TG levels. |
| Synonyms | Icosapent ethyl, 顺-二十碳五烯酸乙酯, EPA ethyl ester, Ethyl eicosapentaenoate |
| molecular weight | 330.5 |
| Molecular formula | C22H34O2 |
| CAS | 86227-47-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 33.33 mg/mL (100.85 mM), Sonication is recommended. Ethanol: 50 mg/mL (151.29 mM), Sonication is recommended. |
| References | 1. Bays H E , Braeckman R A , Ballantyne C M , et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).[J]. Journal of Clinical Lipidology, 2012, 6(6):565-572. 2. Bays HE, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from theMulti-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension[MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682-690. 3. Jacobson TA. A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-695. |